Evidence map›Paper›PMID 40709247›Full record

ArticleResearch square2025

BCL-2 Inhibition via Venetoclax at ART Initiation Induces Long-Term Reduction of the Intact SIV Reservoir.

Tomas Raul Wiche Salinas, Justin Harper, Claire Deleage, Kevin Nguyen, James Auger, Hannah R Flores, Amelia C Wilkes, Rachelle L Stammen, Jennifer S Wood, Gregory K Tharp and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Tomas Raul Wiche SalinasDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0001-8806-4700
Justin HarperDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0002-6948-3501
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-3507-0055
Kevin NguyenDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
James AugerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Hannah R FloresDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Amelia C WilkesDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Rachelle L StammenDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Jennifer S WoodDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Gregory K TharpDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0003-3075-755X
Steven E BosingerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0002-2116-5061
Mackenzie L CottrellDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Emek KoseAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Taina T ImmonenAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Gregory M LairdAccelevir Diagnostics, Baltimore, Maryland, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-2381-1151
R Brad JonesInfectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-4470-1231
Andrew D BadleyDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Deanna A KulpaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0002-0411-7295
Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0002-7276-3600

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Prime shock and kill for HIV erradicationR01AI110173 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2014 to 2024
$6.9M
Centralized Resource to Accurately Quantify Latent and Expressed HIV ReservoirsU24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI LAIRD, GREGORY MICHAEL, MARTIN, ALBINE · 2020 to 2024
$4.9M
Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirsR24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI Gregory Michael Laird, Albine Martin · 2025 to 2026
$2.1M
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985k
NCI NIH HHS 75N91019D00024NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI110173NIAID NIH HHS R24 AI143502NIAID NIH HHS U24 AI143502NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS S10 OD026799
6 · The paper itself

Abstract

The anti-apoptotic molecule BCL-2 favors the maintenance of the CD4

Identifiers

PMID40709247
PMCPMC12288516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.